Collectively, these findings demonstrate that specifically targeting the TNF–TNFR2 axis (as opposed to the TNF–TNFR1 axis) may be a novel therapeutic avenue for asthma and could reduce adverse effects associated with pre-existing anti-TNF agents. This evidence concerns the gene TNFRSF1B and asthma.